Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma

• Published in: World journal of gastroenterology : WJG Vol. 17; no. 44; pp. 4917 - 4921
• Main Author: Liu, Ji-Bin
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Co., Limited 28.11.2011
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Adaptor Proteins, Signal Transducing - metabolism; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Brief; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - prevention & control; Core Binding Factor Alpha 3 Subunit - genetics; Core Binding Factor Alpha 3 Subunit - metabolism; DNA Methylation; DNA甲基化; Esophageal Neoplasms - genetics; Esophageal Neoplasms - pathology; Esophageal Neoplasms - prevention & control; Female; Humans; Intercellular Signaling Peptides and Proteins - genetics; Intercellular Signaling Peptides and Proteins - metabolism; Male; Membrane Proteins - genetics; Membrane Proteins - metabolism; Middle Aged; Promoter Regions, Genetic; Repressor Proteins - genetics; Repressor Proteins - metabolism; ROC Curve; Secondary Prevention; Wnt Proteins - antagonists & inhibitors; Wnt Signaling Pathway - physiology; Wnt信号通路; 复发; 拮抗剂; 血浆; 预测; 食管癌; 鳞状细胞癌; Plasma; Recurrence; Esophageal Cancer; Methylation
• ISSN: 1007-9327; 2219-2840; 2219-2840
• DOI: 10.3748/wjg.v17.i44.4917

AIM：To detect the effects of plasma DNA methylation of Wnt antagonists/inhibitors on recurrence of esophageal squamous cell carcinoma（ESCC）.METHODS：We used methylation-specific polymerase chain reaction to detect hypermethylation of the promoter of four Wnt antagonists/inhibitors（SFRP-1,WIF-1,DKK-3 and RUNX3） using DNA from the plasma of ESCC patients（n = 81） and analyzed the association between promoter hypermethylation of Wnt pathway modulator genes and the two-year recurrence of ESCC.RESULTS：Hypermethylation of SFRP-1,DKK-3 and RUNX-3 was significantly associated with an increased risk of ESCC recurrence（P = 0.001,0.003 and 0.001 for SFRP-1,DKK-3 and RUNX3,respectively）.Patients carrying two to three methylated genes had a significantly elevated risk of recurrence compared with those not carrying methylated genes（odds ratio = 15.69,95% confidential interval：2.97-83）.The area under the receiver operating characteristic curve（AUC） was 77.1 for ESCC recurrence prediction（sensitivity = 66.67 and specificity = 83.3）.When combining methylated genes and the clinical stage,the AUC was 83.69,with a sensitivity of 76.19 and a specificity of 83.3.CONCLUSION：The status of promoter hypermethylation of Wnt antagonists/inhibitors in plasma may serve as a non-invasive prognostic biomarker for ESCC.